William Blair & Company
AXDX

William Blair & Company’s Accelerate Diagnostics AXDX Stock Holding History

William Blair & Company’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,588
Closed -$32.1K – 1812
2023
Q1 		$32.1K Hold
4,588
– – ﹤0.01% 1642
2022
Q4 		$32.4K Sell
4,588
-12,366
-73% -$135K ﹤0.01% 1632
2022
Q3 		$258K Buy
16,954
+11,460
+209% +$190K ﹤0.01% 1293
2022
Q2 		$55K Sell
5,494
-61,216
-92% -$541K ﹤0.01% 1614
2022
Q1 		$961K Sell
66,710
-720
-1% -$20.5K ﹤0.01% 937
2021
Q4 		$3.52M Sell
67,430
-20,289
-23% -$1.13M 0.01% 576
2021
Q3 		$5.11M Buy
87,719
+2,660
+3% +$173K 0.02% 453
2021
Q2 		$6.86M Sell
85,059
-364
-0.4% -$28.9K 0.02% 392
2021
Q1 		$7.11M Buy
85,423
+58,972
+223% +$5.98M 0.03% 383
2020
Q4 		$2M Sell
26,451
-24,694
-48% -$2.21M 0.01% 650
2020
Q3 		$5.45M Sell
51,145
-2,085
-4% -$289K 0.02% 380
2020
Q2 		$8.07M Sell
53,230
-337
-0.6% -$33.2K 0.04% 296
2020
Q1 		$4.46M Sell
53,567
-983
-2% -$138K 0.03% 356
2019
Q4 		$9.22M Sell
54,550
-25,892
-32% -$4.27M 0.05% 277
2019
Q3 		$14.9M Buy
80,442
+4,812
+6% +$930K 0.09% 206
2019
Q2 		$17.3M Buy
75,630
+6,178
+9% +$1.21M 0.1% 191
2019
Q1 		$14.6M Buy
69,452
+5,485
+9% +$1.03M 0.09% 206
2018
Q4 		$7.36M Sell
63,967
-23,899
-27% -$3.54M 0.05% 274
2018
Q3 		$20.2M Buy
87,866
+23,341
+36% +$5.16M 0.12% 169
2018
Q2 		$14.4M Buy
64,525
+1,431
+2% +$320K 0.1% 196
2018
Q1 		$14.4M Sell
63,094
-38,882
-38% -$10.2M 0.1% 188
2017
Q4 		$26.7M Buy
101,976
+7,247
+8% +$1.7M 0.18% 129
2017
Q3 		$21.3M Buy
94,729
+15,981
+20% +$3.93M 0.16% 143
2017
Q2 		$21.5M Buy
78,748
+10,327
+15% +$2.8M 0.16% 147
2017
Q1 		$17.3M Buy
68,421
+4,652
+7% +$1.06M 0.14% 166
2016
Q4 		$13.2M Buy
63,769
+10,725
+20% +$2.55M 0.12% 182
2016
Q3 		$14.5M Buy
53,044
+26,174
+97% +$5.79M 0.13% 179
2016
Q2 		$3.87M Buy
26,870
+19,045
+243% +$2.55M 0.04% 332
2016
Q1 		$1.12M Buy
7,825
+4,591
+142% +$648K 0.01% 594
2015
Q4 		$694K Buy
3,234
+1,372
+74% +$250K 0.01% 723
2015
Q3 		$301K Sell
1,862
-18,816
-91% -$4.07M ﹤0.01% 1141
2015
Q2 		$5.34M Buy
20,678
+19,518
+1,683% +$4.66M 0.01% 1056
2015
Q1 		$261K Sell
1,160
-750
-39% -$157K ﹤0.01% 1929
2014
Q4 		$366K Hold
1,910
– – ﹤0.01% 1787
2014
Q3 		$410K Buy
1,910
+200
+12% +$38.9K ﹤0.01% 1743
2014
Q2 		$444K Buy
1,710
+628
+58% +$137K ﹤0.01% 1698
2014
Q1 		$235K Buy
+1,082
New +$160K ﹤0.01% 1847

Other funds holding AXDX

GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair & Company's AXDX Position: Q2 2023 in Review

William Blair & Company sold out of Accelerate Diagnostics (AXDX) in Q2 2023, closing a stake of 4,588 shares — an estimated $32.1K sold.

William Blair & Company first reported a position in AXDX in Q1 2014 and held it in 37 quarters. The position peaked at $26.7M in Q4 2017. 50 funds tracked by Wall St. Rank hold AXDX as of Q2 2023.

  • William Blair & Company reported no remaining Accelerate Diagnostics position as of Q2 2023 after selling out during the quarter.
  • William Blair & Company sold 4,588 Accelerate Diagnostics shares in Q2 2023, an estimated $32.1K.
  • William Blair & Company first reported a position in Accelerate Diagnostics in Q1 2014 and held it in 37 quarters.
  • William Blair & Company's Accelerate Diagnostics position peaked at $26.7M in Q4 2017.
  • 50 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2023.

Based on William Blair & Company's 13F filing for Q2 2023, filed 11 Aug 2023.